Beaumont Hospital - Dearborn

Summary

Beaumont Hospital - Dearborn is a medical facility located in Dearborn, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Fallopian Tube Cancer and other specialties. Beaumont Hospital - Dearborn is involved with conducting 237 clinical trials across 361 conditions. There are 24 research doctors associated with this hospital, such as Tareq Al Baghdadi, Laura K. Gowans, Philip J. Stella, and Samir Narayan.

Top PIs

Clinical Trials running at Beaumont Hospital - Dearborn

Ovarian Cancer

Lung Cancer

Breast Cancer

Cancer

Breast cancer

Esophageal cancer

Colorectal Cancer

Bladder Cancer

Pancreatic Cancer

Esophageal Carcinoma

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Recruiting

1 award

N/A

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria